• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Agilent (A) Stock May Be 9% Undervalued Following TapeStationDx Launch

    Simply Wall St·09/24/2026 22:27:24
    Listen to the news

    Agilent Technologies has delivered a strong share price run in recent years, which puts a spotlight on whether the current US$172.84 level lines up with the cash the business is expected to generate. Investors now have to weigh that market enthusiasm against what a Discounted Cash Flow (DCF) view of Agilent's future cash streams suggests about its intrinsic value.

    • Over the past 3 years, Agilent Technologies has returned 57.9%, which puts a lot of past optimism on the line when you test the current price against the cash it can produce.
    • New TapeStationDx systems aimed at clinical next generation sequencing quality control may support expectations for future cash flows if they gain traction in regulated labs and help deepen Agilent's position in life sciences workflows.
    • Prefer to judge Agilent Technologies on earnings? See why Agilent Technologies's 33.8x P/E tells a different valuation story.

    For investors, the debate is whether Agilent Technologies' recent share price level is adequately supported by the cash flows implied in its intrinsic value estimate from a Discounted Cash Flow model.

    If you are weighing Agilent Technologies through the lens of its cash flows, it can help to compare that picture with other businesses screened for 30 high quality undervalued stocks

    Is Agilent Technologies Fairly Priced on Cash Flow?

    The Discounted Cash Flow (DCF) approach here uses Agilent Technologies' recent and projected free cash generation to frame what the current equity price is paying for. Latest twelve month Free Cash Flow sits at about $1.21b, and the model expects this to grow over time, with projected annual free cash flows reaching into the mid $2b range and above by the early 2030s.

    Those cash flow assumptions suggest a business that is treated as a steady compounder rather than a turnaround story, which helps explain why the DCF outcome comes out broadly in line with the current $172.84 share price. News around the TapeStationDx launch for clinical next generation sequencing quality control fits that picture, because it points to incremental support for future cash flows rather than a step change. That makes the current DCF view most useful as a check on how much growth in areas like regulated lab workflows is already reflected in the market value. Find out what Agilent Technologies could be worth using our Discounted Cash Flow (DCF) estimate.

    The Agilent Technologies Narrative: What Would Justify Today's Price?

    Simply Wall St Narratives pick up where the DCF puzzle for Agilent Technologies leaves off by spelling out which paths for growth, profitability and earnings would need to play out for the stock to be worth materially more or materially less than today's level, all housed on the Community page. Each narrative ties its implied valuation back to a specific view of how Agilent Technologies' revenue profile, margins and risk mix could evolve, which gives you something concrete to revisit as fresh information comes through.

    One of the top community narratives on Agilent Technologies: roughly fairly valued

    "Strategic investments in higher-margin recurring revenue streams including consumables, software, services, and digital platforms are gaining traction…"

    Discover why this Narrative puts Agilent Technologies at roughly fairly valued.

    The Agilent Technologies share price is only one piece of the investment puzzle

    Before you stop at what Agilent Technologies is worth on cash flows, it pays to look at who is steering the business and how their pay lines up with your interests. See who runs Agilent Technologies and how they are paid.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.